Updates are available Correction dated 2022-05-04
Click to view Correction: https://doi.org/10.1007/s10549-022-06613-4
-
Authors
Geyer, Charles E. Jr. http://orcid.org/0000-0003-0956-151X
Bandos, Hanna
Rastogi, Priya
Jacobs, Samuel A.
Robidoux, André
Fehrenbacher, Louis
Ward, Patrick J.
Polikoff, Jonathan
Brufsky, Adam M.
Provencher, Louise
Paterson, Alexander H. G.
Hamm, John T.
Carolla, Robert L.
Baez-Diaz, Luis
Julian, Thomas B.
Swain, Sandra M.
Mamounas, Eleftherios P.
Wolmark, Norman
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct00087178 at ClinicalTrials.govDocuments that mention this clinical trial
Behavioral and health outcomes from the NRG Oncology/NSABP B-36 trial comparing two different adjuvant therapy regimens for early-stage node-negative breast cancer
https://doi.org/10.1007/s10549-021-06475-2
Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology)
https://doi.org/10.1007/s10549-021-06417-y
-
Funding
Funding for this research was provided by:
National Institutes of Health (UG1CA189867, U10-44066, U10-180868)
Pharmacia
- License Information
-
More Information
Article History
Received: 23 August 2021
Accepted: 10 October 2021
First Online: 1 March 2022
Change Date: 4 May 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s10549-022-06613-4
Declarations
:
: Charles E. Geyer, Jr.—Grants, non-financial support and other from Genentech/Roche, Daiichi/Sankyo, and AstraZeneca, during the conduct of the study, and personal fees from Exact Sciences and Athenex, outside the submitted work. Priya Rastogi: Genentech/Roche—Unpaid advisory boards, travel, accommodations; Lilly—Travel, accommodations; Astra/Zeneca—Travel, accommodations. Johnathan Polikoff – Consultant, Natera. Louise Provencher: Consulting or Advisory Role: Lilly, Pfizer, Roche, Novartis; Research Funding: Pfizer, Roche, Novartis, Merck, GlaxoSmithKline, Odonate Therapeutics Sandra M. Swain: Personal Fees for consulting/advisory services/nonpromotional speaking: Astra-Zeneca, Athenex, Daiichi-Sankyo, Genentech/Roche, Exact Sciences (Genomic Health), Eli Lilly and Company, Bejing Medical Award Association, Merck, Natera, Molecular Templates, Silverback Therapeutics; Non-financial support (i.e., travel, accommodations, and/or food & beverage); Genentech/Roche: Research support (to institution): Genentech/Roche, Kailos Genetics; Other support: AstraZeneca (member, independent data monitoring committee) and Genentech/Roche (third-party writing assistance). Eleftherios P. Mamounas: Genentech/Roche, Exact Sciences: Consultant (Advisory Board) and Speaker’s Bureau. Biotheranostics, Daiichi Sankyo, Puma Biotechnology, Merck: Consultant (Advisory Board).
